-+ 0.00%
-+ 0.00%
-+ 0.00%

Agenus reports Phase 1b BOT+BAL trial shows 17% response in post-immunotherapy HCC

PUBT·05/15/2026 20:11:29
Listen to the news
Agenus reports Phase 1b BOT+BAL trial shows 17% response in post-immunotherapy HCC
  • Agenus reported Phase 1b results already published in Liver Cancer on botensilimab with balstilimab in advanced hepatocellular carcinoma patients whose disease progressed following prior immunotherapy.
  • Study showed signs of tumor shrinkage in some patients, with durable disease control in others, supporting potential activity in a setting with limited post-immunotherapy options.
  • Safety profile was described as manageable and consistent with earlier experience, with no treatment-related deaths or new safety signals.
  • Findings support continued clinical development of botensilimab-based combinations in post-immunotherapy liver cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260515976818) on May 15, 2026, and is solely responsible for the information contained therein.